Browsing by Issue Date, starting with "2011-12"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Cirurgia Laser CO2 no Tratamento de Tumores Malignos GlóticosPublication . Jerónimo, A; Cavilhas, P; Oliveira, L; Montalvão, P; Magalhães, MIntrodução: A microcirurgia transoral com laser CO2 (MTOL) é uma alternativa no tratamento de tumores malignos glóticos. Material e Métodos: Estudo retrospectivo dos doentes submetidos a MTOL, de Janeiro de 2000 a Dezembro de 2005, incluindo apenas os casos em que o laser constituiu o tratamento primário. Resultados: Total de 45 doentes: CIS (n=9), T1a (n=29), T1b (n=5), T2 (n=1), T3 (n=1), com follow-up médio de 63,5 meses. Obteve-se uma taxa de recidiva local global de 22,2%, verificando-se o envolvimento da comissura anterior em 40% das recidivas. A taxa de sobrevida global e livre de doença, aos 5 anos, foi de 82,2%, com uma taxa de preservação laríngea de 89,2%. Conclusão: O laser CO2 é uma opção eficaz na abordagem de neoplasias glóticas em estadio inicial. A taxa de recidiva tumoral é maior quando há tumor na margem e/ou envolvimento da comissura anterior. Tumores glóticos localmente avançados são mais susceptíveis ao insucesso terapêutico por esta técnica.
- The 10th Anniversary of the Junior Members and Affiliates of the European Academy of Allergy and Clinical ImmunologyPublication . Skevaki, C; Maggina, P; Santos, A; Rodrigues-Alves, R; Antolin-Amerigo, D; Borrego, LM; Bretschneider, I; Butiene, I; Couto, M; Fassio, F; Gardner, J; Xatzipsalti, M; Hovhannisyan, L; Hox, V; Makrinioti, H; O Neil, S; Pala, G; Rudenko, M; Santucci, A; Seys, S; Sokolowska, M; Whitaker, P; Heffler, EThis year is the 10th anniversary of the European Academy of Allergy and Clinical Immunology (EAACI) Junior Members and Affiliates (JMAs). The aim of this review is to highlight the work and activities of EAACI JMAs. To this end, we have summarized all the initiatives taken by JMAs during the last 10 yr. EAACI JMAs are currently a group of over 2380 clinicians and scientists under the age of 35 yr, who support the continuous education of the Academy's younger members. For the past decade, JMAs enjoy a steadily increasing number of benefits such as free online access to the Academy's journals, the possibility to apply for Fellowships and the Mentorship Program, travel grants to attend scientific meetings, and many more. In addition, JMAs have been involved in task forces, cooperation schemes with other scientific bodies, organization of JMA focused sessions during EAACI meetings, and participation in the activities of EAACI communication platforms. EAACI JMA activities represent an ideal example of recruiting, training, and educating young scientists in order for them to thrive as future experts in their field. This model may serve as a prototype for other scientific communities, several of which have already adapted similar policies.
- Radix Nasi Transposition Flap for Medial Canthus and Nasal Sidewall DefectsPublication . Carvalho, R; Casal, D; Zagalo, C; Rosa, J
- The Dark Side of SAPHO SyndromePublication . Coelho Henriques, C; Sousa, M; Panarra, A; Riso, NSAPHO syndrome (synovitis, acne, pustulosis, hyperostosis and osteitis) is a relatively rare entity. The therapeutic approach of patients with SAPHO syndrome has included multiple drugs with varying success and incoherence responses. The therapy is still empirical today. SAPHO syndrome is commonly treated with non-steroidal anti-inflammatory drugs, bisphophonates and non-biologic disease modifying antirheumatic drugs. Recent reports showed successful treatment with tumour necrosis factor α (TNF α) antagonists, but there is still a dark side of SAPHO syndrome including a subgroup of patient's refractory to all the treatments that have been empirically experienced. A clinical report of a patient with SAPHO syndrome with 12 years of evolution is described. All the therapeutic approaches, including anti TNF α therapy, have not prevented the clinical and radiographic progression of the disease. Given that the disease affects mostly younger patients, new therapeutic strategies are necessary in order to avoid potentially irreversible joint and bone lesions.